Skip to main content
Erschienen in: World Journal of Surgery 7/2016

01.09.2015 | Original Scientific Report

A Comparative Validation of Primary Surgical Versus Post-neo-adjuvant Chemotherapy Sentinel Lymph Node Biopsy for Stage III Breast Cancers

verfasst von: Gaurav Agarwal, Sendhil Rajan, Sanjay Gambhir, Punita Lal, Narendra Krishnani, Subhash Kheruka

Erschienen in: World Journal of Surgery | Ausgabe 7/2016

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Sentinel lymph node biopsy (SLNB) is the standard of care for staging N0 primary early breast cancers (EBC). Patients in developing countries mostly present with large (LOBC) or locally advanced cancers (LABC) and are treated with neo-adjuvant chemotherapy (NACT). Accuracy of SLNB in staging stage III N0 and post-NACT N0 patients is uncertain. This prospective validation study on LOBC/LABC patients compared the accuracy of SLNB between primary versus post-NACT surgery.

Materials and methods

Fifty T3/T4, N0 patients undergoing primary surgery (Group I) and 70 LOBC/LABC (index stage) treated with NACT and N0 at the time of surgery (Group II) were inducted. Validation SLNB was performed using low-cost methylene-blue and 99mTc-Antimony colloid. SLN identification (IR) and false-negative (FNR) rates were compared between the groups. Sub-group analysis was done in Group II per index tumor and nodal stage to identify factors predicting SLN IR and FNR in post-NACT patients. SLN IR and FNR in both groups were compared with those in previously published SLN validation study and meta-analysis in EBC.

Results

Using combination of blue-dye and radio-colloid, post-NACT SLN IR and FNR (82.9, 13.5 %) were far inferior to T3/T4 primary surgery group (94, 7.7 %; p values 0.034, 0.041) and in EBC. SLN IR using blue-dye alone was dismally low in post-NACT LABCs. Factors predicting unidentified post-NACT SLN and false-negative SLNB included young age, LVI, skin infiltration, extra-nodal spread or N2a stage, and UOQ tumors.

Conclusions

Accuracy of SLNB in T3, N0 tumors undergoing primary surgery is comparable to that of SLNB for N0 EBC. In post-NACT patients, SLNB IR are lower and FNR are higher. Factors predictive of non-identification and false-negative SLNB include pre-NACT skin involvement (T4b), N2a stage or extra-nodal invasion and LVI, and to a lesser extent, young age and UOQ location of the tumor.
Literatur
1.
Zurück zum Zitat Krag DN, Anderson SJ, Julian TB et al (2007) Technical outcomes of sentinel-lymphnode resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol. 8:881–888CrossRefPubMed Krag DN, Anderson SJ, Julian TB et al (2007) Technical outcomes of sentinel-lymphnode resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol. 8:881–888CrossRefPubMed
2.
Zurück zum Zitat Latosinsky S, Dabbs K, Moffat F (2008) Evidence-based reviews in surgery group. Canadian Association of General Surgeons and American College of Surgeons Evidence-Based Reviews in Surgery. 27. Quality-of-life outcomes with sentinel node biopsy versus standard axillary treatment in patients with operable breast cancer. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. Can J Surg 51(6):483–485PubMedPubMedCentral Latosinsky S, Dabbs K, Moffat F (2008) Evidence-based reviews in surgery group. Canadian Association of General Surgeons and American College of Surgeons Evidence-Based Reviews in Surgery. 27. Quality-of-life outcomes with sentinel node biopsy versus standard axillary treatment in patients with operable breast cancer. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. Can J Surg 51(6):483–485PubMedPubMedCentral
3.
Zurück zum Zitat Chung MH, Ye W, Giuliano AE (2001) Role for sentinel lymph node dissection in the management of large (> or = 5 cm) invasive breast cancer. Ann Surg Oncol 8:688–692PubMed Chung MH, Ye W, Giuliano AE (2001) Role for sentinel lymph node dissection in the management of large (> or = 5 cm) invasive breast cancer. Ann Surg Oncol 8:688–692PubMed
4.
Zurück zum Zitat Wong SL, Chao C, Edwards MJ et al. (2002) Accuracy of sentinel lymph node biopsy for patients with T2 and T3 breast cancers. Am Surg. 2001 Jun;67(6):522–6; discussion 527–8. Erratum in: Am Surg 68(5):503 Wong SL, Chao C, Edwards MJ et al. (2002) Accuracy of sentinel lymph node biopsy for patients with T2 and T3 breast cancers. Am Surg. 2001 Jun;67(6):522–6; discussion 527–8. Erratum in: Am Surg 68(5):503
5.
Zurück zum Zitat Beumer JD, Gill G, Campbell I et al (2014) Sentinel node biopsy and large (≥3 cm) breast cancer. ANZ J Surg. 84(3):117–120CrossRefPubMed Beumer JD, Gill G, Campbell I et al (2014) Sentinel node biopsy and large (≥3 cm) breast cancer. ANZ J Surg. 84(3):117–120CrossRefPubMed
6.
Zurück zum Zitat Agarwal G, Gambhir S, Lal P et al (2011) Sentinel lymph node biopsy in large node negative breast cancer: results of a validation study using low-cost blue dye & 99mTc-antimony colloid. Breast J 20(Suppl 1):S60CrossRef Agarwal G, Gambhir S, Lal P et al (2011) Sentinel lymph node biopsy in large node negative breast cancer: results of a validation study using low-cost blue dye & 99mTc-antimony colloid. Breast J 20(Suppl 1):S60CrossRef
7.
Zurück zum Zitat Boughey JC, Suman VJ, Mittendorf EA, Alliance for Clinical Trials in Oncology et al (2013) Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA 310(14):1455–1461CrossRefPubMedPubMedCentral Boughey JC, Suman VJ, Mittendorf EA, Alliance for Clinical Trials in Oncology et al (2013) Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA 310(14):1455–1461CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Hennessy BT, Hortobagyi GN, Rouzier R et al (2005) Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol 23(36):9304–9311CrossRefPubMed Hennessy BT, Hortobagyi GN, Rouzier R et al (2005) Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol 23(36):9304–9311CrossRefPubMed
11.
Zurück zum Zitat Fitzgibbons PL, Page DL, Weaver D et al (2000) Prognostic factors in breast cancer. College of American Pathologists consensus statement 1999. Arch Pathol Lab Med 124:966–978PubMed Fitzgibbons PL, Page DL, Weaver D et al (2000) Prognostic factors in breast cancer. College of American Pathologists consensus statement 1999. Arch Pathol Lab Med 124:966–978PubMed
12.
Zurück zum Zitat Lyman GH, Giuliano AE, Somerfield MR et al (2005) American Society of Clinical Oncology Guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 23:7703–7720CrossRefPubMed Lyman GH, Giuliano AE, Somerfield MR et al (2005) American Society of Clinical Oncology Guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 23:7703–7720CrossRefPubMed
13.
Zurück zum Zitat Agarwal G, Gambhir S, Kheruka S et al (2005) Low-cost sentinel node studies in breast cancer with indigenous blue dye & 99mTc-antimony colloid. J Jpn Surg Soc 106:221 Agarwal G, Gambhir S, Kheruka S et al (2005) Low-cost sentinel node studies in breast cancer with indigenous blue dye & 99mTc-antimony colloid. J Jpn Surg Soc 106:221
15.
Zurück zum Zitat Bedrosian I, Reynolds C, Mick R et al (2000) Accuracy of sentinel lymph node biopsy in patients with large primary breast tumors. Cancer 88(11):2540–2545CrossRefPubMed Bedrosian I, Reynolds C, Mick R et al (2000) Accuracy of sentinel lymph node biopsy in patients with large primary breast tumors. Cancer 88(11):2540–2545CrossRefPubMed
16.
Zurück zum Zitat Schüle J, Frisell J, Ingvar C, Bergkvist L (2007) Sentinel node biopsy for breast cancer larger than 3 cm in diameter. Br J Surg 94(8):948–951CrossRefPubMed Schüle J, Frisell J, Ingvar C, Bergkvist L (2007) Sentinel node biopsy for breast cancer larger than 3 cm in diameter. Br J Surg 94(8):948–951CrossRefPubMed
17.
Zurück zum Zitat Boughey JC, Suman VJ, Mittendorf EA et al (2015) Alliance for Clinical Trials in Oncology. Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 (Alliance). Ann Surg 261(3):547–552CrossRefPubMedPubMedCentral Boughey JC, Suman VJ, Mittendorf EA et al (2015) Alliance for Clinical Trials in Oncology. Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 (Alliance). Ann Surg 261(3):547–552CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Mamounas EP, Brown A, Anderson S et al. (2005) Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 23(12):2694–702. Erratum in: J Clin Oncol. 2005 Jul 20;23(21):4808 Mamounas EP, Brown A, Anderson S et al. (2005) Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 23(12):2694–702. Erratum in: J Clin Oncol. 2005 Jul 20;23(21):4808
19.
Zurück zum Zitat Takahashi M, Jinno H, Hayashida T et al (2012) Correlation between clinical nodal status and sentinel lymph node biopsy false negative rate after neoadjuvant chemotherapy. World J Surg 36(12):2847–2852. doi:10.1007/s00268-012-1704-z CrossRefPubMed Takahashi M, Jinno H, Hayashida T et al (2012) Correlation between clinical nodal status and sentinel lymph node biopsy false negative rate after neoadjuvant chemotherapy. World J Surg 36(12):2847–2852. doi:10.​1007/​s00268-012-1704-z CrossRefPubMed
20.
Zurück zum Zitat Fu JF, Chen HL, Yang J et al (2014) Feasibility and accuracy of sentinel lymph node biopsy in clinically node-positive breast cancer after neoadjuvant chemotherapy: a meta-analysis. PLoS One. 9(9):e105316CrossRefPubMedPubMedCentral Fu JF, Chen HL, Yang J et al (2014) Feasibility and accuracy of sentinel lymph node biopsy in clinically node-positive breast cancer after neoadjuvant chemotherapy: a meta-analysis. PLoS One. 9(9):e105316CrossRefPubMedPubMedCentral
Metadaten
Titel
A Comparative Validation of Primary Surgical Versus Post-neo-adjuvant Chemotherapy Sentinel Lymph Node Biopsy for Stage III Breast Cancers
verfasst von
Gaurav Agarwal
Sendhil Rajan
Sanjay Gambhir
Punita Lal
Narendra Krishnani
Subhash Kheruka
Publikationsdatum
01.09.2015
Verlag
Springer International Publishing
Erschienen in
World Journal of Surgery / Ausgabe 7/2016
Print ISSN: 0364-2313
Elektronische ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-015-3222-2

Weitere Artikel der Ausgabe 7/2016

World Journal of Surgery 7/2016 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.